Tia sodium powder

Product introduction：

CAS: 30123-17-2

Appearance: White to yellowish powder

Purity: ≥99%

Solubility: freely soluble In water and methanol and dichloromethane

Any impurity: ≤0.1%

Total impurities: ≤0.4%

Overview: Tia sodium powder also named tianeptine sodium powder, is is a prescription drug for depression in some European, Asian, and Latin American countries. Tianeptine is most commonly used for depression. It is also used for pain, asthma, anxiety, and other conditions.

Associated Conditions: Major Depressive Disorder (MDD)

Application: Prescription tianeptine is used to reduce depressive symptoms in people with depression. It might work as well as certain other medicines commonly used for depression.

Dosage: Adults, 25 or 37.5 mg of tianeptine daily has been used as a prescription drug under the guidance of a health care professional.

Other chemical names: Tianeptine sodium salt, S-1574, Stablon, Coaxil sodiuM salt, Tianeptine sodium salt hydrate,

7-[(3-Chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic Acid S,S-Dioxide Sodium Salt

Biochem/physiol Actions:

Tianeptine is a tricyclic antidepressant that enhances serotonin uptake. This drug can affect neuroprotection, neuronal excitability, memory and anxiety. However, tianeptine is not linked to adverse psychomotor, cognitive, cardiovascular, sleep and bodyweight effects. The drug has a low tendency for abuse and has a positive pharmacokinetic profile.
Tianeptine is least involved in drug interaction as it is not metabolized by cytochrome P450 system in the liver. In hippocampus and amygdala, tianeptine is involved in glutamatergic transmission processes and elicits neuroplasticity.

Description:

Tianeptine sodium salt is a salt of Tianeptine. Tianeptine is an atypical antidepressant. It is an agonist of the μ-opioid receptor (MOR; EC50s = 194 and 641 nM for human and mouse receptors, respectively, in a BRET assay for G protein activation) and also has effects on the glutamate system. Tianeptine (30 mg/kg) decreases immobility in the forced swim test in wild-type, but not MOR knockout mice, indicating antidepressant-like activity dependent on MORs. It increases locomotor activity at a dose of 30, but not 10 mg/kg, in the open field test and increases paw withdrawal latency in the hot-plate test in mice. Tianeptine modulates AMPA receptor activity by increasing phosphorylation of the AMPA receptor GluR1 subunit in the frontal cortex and hippocampal CA3 region in mice. It prevents increases in glial glutamate transporter 1 (GLT-1) expression induced by chronic restraint stress in the hippocampal CA3 region in rats when administered at a dose of 10 mg/kg per day for 21 days.5It also reverses increases in extracellular glutamate levels induced by acute restraint stress in the basolateral nucleus of the amygdala in rats

Certificate of analysia